Just putting forward another point of view for consideration.The recent quote below is not hard to find [completely ignores the substantial Australian income tax payment] and implies a very negative and downbeat outlook:
"Neuren Pharmaceuticals Ltd reported a significant decrease in profit after tax for the first half of 2024, earning A$8.0 million compared to A$47.8 million in the same period last year, a drop of 83%. Despite a substantial increase in royalty revenue from Acadia, the absence of milestone revenue recognized in the previous year heavily impacted the overall earnings. No dividends were paid or declared, and the company anticipates a future milestone revenue of A$77 million related to DAYBUE sales".
Kens
NEU chart, page-1894
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.75 |
Change
0.190(1.40%) |
Mkt cap ! $1.757B | |||
| Open | High | Low | Value | Volume |
| $13.49 | $13.82 | $13.30 | $4.831M | 355.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1607 | $13.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.75 | 626 | 3 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |